Fig. 1

Identification of POU6F2-AS1 and analysis of its clinical significance in CRC. (A) Venn diagram for upregulated lncRNA in GEO datasets. (B) Comparison of POU6F2-AS1 expression status between different cancers or specific cancer subtypes and normal tissues in TCGA database. (C) The POU6F2-AS1 expression between CRC tissues and normal samples in TCGA database. (D) The POU6F2-AS1 expression between CRC tissues and paired normal samples in TCGA database. (E) The expression of POU6F2-AS1 was evaluated in different groups stratified according to clinical stages. (F) Relative expression of POU6F2-AS1 in a human normal colorectal epithelium cell line (FHC) and CRC cell lines (HCT116, SW480, DLD1, SW620, HT29 and LoVo). (G) Comparison of the relative POU6F2-AS1 expression between CRC tissues and paired ANTs (case = 84). (H) Representative images showing the expression of POU6F2-AS1 in CRC TMAs detected by FISH staining. (I) Kaplan-Meier analysis of the OS rate in CRC patients according to POU6F2-AS1 expression based on TMAs cohort (P < 0.001). (J) The OS survival curves of POU6F2-AS1 in GSE16125 database (P = 0.0117). (K, L) Univariate and Multivariate analyses were performed for CRC patients in TMAs. All bars correspond to 95% CIs. HR, hazard ratio CI, confidence interval. CRC, colorectal cancer; AUC, area under the curve. *P < 0.05, **P < 0.01, ***P < 0.001